Verastem, Inc. (NASDAQ:VSTM - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Verastem in a research note issued to investors on Monday, March 24th. HC Wainwright analyst S. Lee expects that the biopharmaceutical company will earn ($0.67) per share for the quarter. HC Wainwright has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Verastem's current full-year earnings is ($3.02) per share. HC Wainwright also issued estimates for Verastem's Q2 2025 earnings at ($0.74) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.62) EPS, FY2026 earnings at ($1.10) EPS and FY2027 earnings at ($0.33) EPS.
Verastem (NASDAQ:VSTM - Get Free Report) last announced its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.57).
Other equities analysts have also recently issued reports about the stock. B. Riley boosted their price objective on shares of Verastem from $7.00 to $9.00 and gave the company a "buy" rating in a research note on Friday, January 31st. Royal Bank of Canada dropped their price target on shares of Verastem from $16.00 to $14.00 and set an "outperform" rating on the stock in a research note on Friday, March 21st. StockNews.com upgraded shares of Verastem from a "sell" rating to a "hold" rating in a research report on Monday, March 24th. Mizuho boosted their target price on Verastem from $7.00 to $9.00 and gave the stock an "outperform" rating in a research report on Thursday, December 19th. Finally, BTIG Research increased their target price on Verastem from $13.00 to $20.00 and gave the stock a "buy" rating in a research note on Tuesday, December 31st. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, Verastem currently has an average rating of "Moderate Buy" and an average target price of $13.88.
View Our Latest Stock Report on VSTM
Verastem Stock Performance
Shares of VSTM stock traded down $0.54 during midday trading on Thursday, hitting $6.19. The company had a trading volume of 810,958 shares, compared to its average volume of 927,347. The stock has a market cap of $318.70 million, a price-to-earnings ratio of -1.94 and a beta of 0.60. The company has a debt-to-equity ratio of 2.77, a current ratio of 3.23 and a quick ratio of 3.23. The company's 50 day simple moving average is $6.14 and its 200 day simple moving average is $4.77. Verastem has a 52-week low of $2.10 and a 52-week high of $13.52.
Insider Transactions at Verastem
In related news, CEO Dan Paterson sold 8,568 shares of the business's stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $5.24, for a total value of $44,896.32. Following the sale, the chief executive officer now directly owns 347,581 shares in the company, valued at $1,821,324.44. The trade was a 2.41 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 9,960 shares of company stock valued at $53,498 in the last quarter. 2.20% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Verastem
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC increased its stake in shares of Verastem by 51.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,997 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 1,698 shares in the last quarter. FMR LLC purchased a new position in Verastem during the third quarter worth $41,000. JPMorgan Chase & Co. raised its holdings in shares of Verastem by 55.4% in the third quarter. JPMorgan Chase & Co. now owns 16,878 shares of the biopharmaceutical company's stock worth $50,000 after acquiring an additional 6,016 shares during the last quarter. ProShare Advisors LLC acquired a new position in shares of Verastem in the fourth quarter worth $56,000. Finally, Voya Investment Management LLC purchased a new stake in shares of Verastem in the fourth quarter valued at $59,000. Institutional investors and hedge funds own 88.37% of the company's stock.
About Verastem
(
Get Free Report)
Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
See Also
Before you consider Verastem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verastem wasn't on the list.
While Verastem currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
